RSS

Valeant

Valeant Pharmaceuticals has announced the formation of a new Patient Access and Pricing Committee that will be responsible for the pricing of the company's drugs Read more

News

Following Turing Pharmaceuticals’ famous 5,000% price hike on critical drug Daraprim, Canadian pharma group Valeant has followed up with a similarly incredulous move Read more

Opinion

Valeant Pharmaceuticals International has completed the sale to Galderma of all rights to Restylane, Perlane, Emervel, Sculptra, and Dysport owned or held by Valeant for $1.4 billion in cash, pursuant to the previously announced agreement with Nestle Read more

Voice of concern: Re-revised proposal creates significant risks and uncertainties for Allergan stockholders, say industry experts Read more

News

Hot pursuit: Valeant Pharmaceuticals is continuing its pursuit to takeover Allergan. On Monday 12 May the American company Allergan, unanimously rejected the offer made by the Canadian company Read more

News